Safety Study of GC1008 in Patients With Focal Segmental Glomerulosclerosis (FSGS) of Single Doses of GC1008 in Patients With Treatment Resistant Idiopathic FSGS

NCT00464321 · clinicaltrials.gov ↗

PHASE1

Phase

COMPLETED

Status

16

Enrollment

INDUSTRY

Sponsor class

Conditions

Focal Segmental Glomerulosclerosis

Interventions

BIOLOGICAL: GC1008
BIOLOGICAL: GC1008
BIOLOGICAL: GC1008
BIOLOGICAL: GC1008

Sponsor

Genzyme, a Sanofi Company